VIPR2 and Parkinson disease: Using murine models of Parkinson’s disease, administration of VPAC2 agonists has been shown to increase Treg activity without altering cell numbers, reduce microglial inflammatory responses, increase survival of dopaminergic neurons, and improve striatal densities [63,296].